SOPHiA GENETICS (NASDAQ:SOPH) Stock: Insider Zhenyu Xu Sells 4,000 Shares

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Zhenyu Xu sold 4,000 shares of the company’s stock in a transaction on Tuesday, October 13th. The stock was sold at an average price of $7.18, for a total transaction of $28,720.00. Following the sale, the insider directly owned 541,493 shares of the company’s stock, valued at approximately $3,887,919.74. This represents a 0.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Zhenyu Xu also recently made the following trade(s):

• On Monday, October 5th, Zhenyu Xu sold 7,394 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $8.12, for a total transaction of $60,039.28.
• On Thursday, August 27th, Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $8.91, for a total transaction of $89,100.00.
• On Thursday, August 13th, Zhenyu Xu sold 4,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.52, for a total transaction of $30,080.00.
• On Friday, August 7th, Zhenyu Xu sold 17,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $7.29, for a total transaction of $123,930.00.
• On Wednesday, August 5th, Zhenyu Xu sold 3,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.00, for a total transaction of $21,000.00.
• On Tuesday, August 4th, Zhenyu Xu sold 10,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $6.92, for a total transaction of $69,200.00.

SOPHiA GENETICS Trading Up 3.3%

Shares of NASDAQ:SOPH opened at $7.29 on Friday. The company has a market cap of $611.59 million, a P/E ratio of -6.34 and a beta of 0.95. The stock’s 50-day moving average is $7.98 and its 200-day moving average is $6.24. SOPHiA GENETICS SA has a 52-week low of $3.75 and a 52-week high of $8.98. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.55 and a current ratio of 2.69.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.05). SOPHiA GENETICS had a negative return on equity of 132.47% and a negative net margin of 93.86%. The business had revenue of $23.31 million during the quarter, compared to the consensus estimate of $21.72 million. Equities research analysts predict that SOPHiA GENETICS SA will post -0.77 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have issued reports on SOPH. Zacks Research raised SOPHiA GENETICS to a “hold” rating in a report on Tuesday, July 21st. BTIG Research upped their price target on SOPHiA GENETICS from $8.00 to $9.00 and gave the stock a “buy” rating in a report on Wednesday, August 5th. HC Wainwright reiterated a “buy” rating and set a $14.00 price target on shares of SOPHiA GENETICS in a report on Monday. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Friday, July 17th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, SOPHiA GENETICS currently has a consensus rating of “Hold” and an average price target of $10.00.

Institutional Trading of SOPHiA GENETICS

Hedge funds have recently bought and sold shares of the stock. AWM Investment Company Inc. acquired a new stake in SOPHiA GENETICS in the 2nd quarter worth $9,809,000. Hodges Capital Management Inc. bought a new position in shares of SOPHiA GENETICS during the 1st quarter worth about $2,157,000. Sei Investments Co. bought a new position in shares of SOPHiA GENETICS during the 1st quarter worth about $1,772,000. Maven Securities LTD acquired a new position in shares of SOPHiA GENETICS during the second quarter valued at about $866,000. Finally, Hennion & Walsh Asset Management Inc. acquired a new position in shares of SOPHiA GENETICS during the second quarter valued at about $567,000. 31.59% of the stock is owned by institutional investors.

About SOPHiA GENETICS

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.